vida: extract claims from 2026-05-07-pmc-glp1-psychiatric-systematic-review-2026

- Source: inbox/queue/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-anhedonia-measurement-gap-creates-monitoring-blind-spot-for-most-reported-psychiatric-adverse-effect.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: No validated clinical instrument prospectively captures GLP-1-induced anhedonia despite widespread clinical reporting, creating systematic under-detection in trials and post-market surveillance
+confidence: experimental
+source: Sa et al. (2026), systematic review finding absence of anhedonia characterization
+created: 2026-05-07
+title: GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
+agent: vida
+sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
+scope: structural
+sourcer: Sa et al. (2026)
+supports: ["glp1-trials-lack-validated-anhedonia-measurement-infrastructure"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
+
+A comprehensive 38-study systematic review found that anhedonia data is 'ABSENT' from GLP-1 psychiatric literature despite being the most commonly reported psychiatric adverse effect in clinical practice. The review notes 'emotional blunting mentioned as potential adverse outcome but no incidence data. Anhedonia not characterized as distinct outcome.' This represents a genuine measurement infrastructure gap, not merely a knowledge gap. Standard depression scales (PHQ-9, HAM-D) used in GLP-1 trials do not isolate anhedonia as a distinct construct, and no GLP-1 trial has prospectively measured anhedonia using validated instruments like the Snaith-Hamilton Pleasure Scale. The clinical significance is that the most frequently reported psychiatric adverse effect is invisible to both clinical trials and pharmacovigilance systems. This creates a monitoring blind spot where patient-reported anhedonia cannot be systematically tracked, quantified, or correlated with dose, duration, or patient characteristics. The review's clinical recommendations include monthly psychiatric monitoring but provide no guidance on anhedonia assessment because no validated protocol exists.

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -49,3 +49,10 @@ Review identifies eating disorder history, perfectionism, OCD traits, and emotio
 **Source:** Lancet Psychiatry 2026, Karolinska Institutet
 
 Swedish study population (95,490 people with pre-existing depression/anxiety) demonstrates that psychiatric comorbidity is both a predictor of GLP-1 prescribing AND a population where the drug shows large protective effects (42% reduction in worsening). This creates a paradox: the population most likely to benefit faces highest discontinuation risk.
+
+
+## Extending Evidence
+
+**Source:** Sa et al. (2026)
+
+Large observational cohort found 195% increased depression risk and 106% increased suicidal behavior risk in obesity patients, though confounding by indication is suspected. This extends the access-adherence trap by showing psychiatric adverse effects may be concentrated in the population with pre-existing psychiatric comorbidity who already face higher discontinuation rates.

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -59,3 +59,10 @@ ISPOR study of 60,000+ GLP-1 users found 1.275% cumulative eating disorder incid
 **Source:** STAT News, April 27, 2026; ISPOR real-world analysis
 
 ISPOR real-world analysis of 60,000+ GLP-1 users found 1.28% diagnosed with eating disorder within two years. This is total incidence in GLP-1 user population without control group comparison. STAT News characterizes the evidence base as 'scant' and quotes expert assessment that 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' The 1.28% rate, if applied to 1-in-8 Americans taking GLP-1s, projects to 420,000+ people developing eating disorders.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Systematic review of 38 studies confirms pharmacovigilance signal for eating disorders is class-wide across GLP-1 receptor agonists and specific to obesity populations. Review found 'elevated suicidal ideation odds ratio 4.45 when concurrently using antidepressants' and notes eating disorder risk is amplified in patients with psychiatric comorbidity.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -107,3 +107,10 @@ Osmind identifies parallel competency gap for psychiatric monitoring: primary ca
 **Source:** Sa et al., Diabetes Obesity and Metabolism 2026
 
 Systematic review explicitly states 'caution is warranted in individuals with anorexia nervosa or restrictive eating patterns' but provides no evidence that pre-treatment screening protocols are being deployed. Most RCTs 'excluded individuals with moderate-to-severe mood disorders,' meaning high-risk populations are routinely excluded from evidence generation.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Review recommends 'monthly check-ins with validated depression/suicidality tools' and 'psychoeducation for patients and caregivers' but provides no operational guidance on eating disorder screening despite acknowledging the risk. This confirms the gap is structural infrastructure, not clinical knowledge.

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -38,3 +38,10 @@ Sensitivity analysis of 2.06M VigiBase reports found NO eating disorder signals
 **Source:** Gill et al., JAMA Psychiatry 2026
 
 First RCT evidence that therapeutic doses in MDD population reduce motivation deficit (opposite of anhedonia induction). The population difference may be critical: MDD patients have baseline reward circuit dysfunction that GLP-1 normalizes, while metabolically healthy patients experience suppression from normal baseline.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Meta-analyses show 'modest antidepressant effects, greater in type 2 diabetes populations' while observational data in obesity populations show '195% increased depression risk and 106% increased suicidal behavior risk.' This confirms directionally opposite effects by population, though confounding by indication complicates interpretation.

domains/health/glp1-psychotropic-co-medication-quadruples-suicidal-ideation-risk-through-pharmacodynamic-interaction.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Concurrent use of GLP-1 receptor agonists with antidepressants or benzodiazepines increases suicidal ideation odds ratio to 4.07-4.45, creating an underappreciated safety signal in primary care prescribing
+confidence: experimental
+source: Sa et al. (2026), pharmacovigilance data from systematic review
+created: 2026-05-07
+title: GLP-1 psychotropic co-medication quadruples suicidal ideation risk through pharmacodynamic interaction
+agent: vida
+sourced_from: health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
+scope: causal
+sourcer: Sa et al. (2026)
+supports: ["glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+related: ["glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations"]
+---
+
+# GLP-1 psychotropic co-medication quadruples suicidal ideation risk through pharmacodynamic interaction
+
+Pharmacovigilance analysis within a 38-study systematic review found elevated suicidal ideation odds ratios of 4.45 for patients concurrently using GLP-1 receptor agonists with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a 4-fold increase in suicidal ideation risk compared to GLP-1 monotherapy. The clinical significance is amplified by the prescribing context: GLP-1s are increasingly prescribed in primary care settings where providers may not have access to patients' psychiatric medication lists or training in psychiatric risk assessment. The interaction appears pharmacodynamic rather than purely confounding-by-indication, as the risk elevation is specific to concurrent use rather than psychiatric history alone. This creates a structural safety gap where the fastest-growing drug class intersects with common psychotropic medications without adequate monitoring infrastructure. The review explicitly recommends 'special caution for psychotropic medication co-users' but provides no operational guidance on how primary care providers should implement this caution.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -157,3 +157,10 @@ Parkinson's motor function improvement across 5 Phase 2 studies provides additio
 **Source:** EVOKE/EVOKE+ trials, Lancet 2026
 
 EVOKE failure in Alzheimer's disease with confirmed pathology defines the boundary condition for GLP-1 CNS efficacy: the drug works through reward/motivation circuits (VTA, NAcc, dopaminergic systems) for SUD and depression, but cannot modify molecular neurodegeneration cascades (amyloid/tau pathology) in established Alzheimer's disease. This mechanistic specificity strengthens the dopaminergic pathway argument by showing what GLP-1 CANNOT do.
+
+
+## Supporting Evidence
+
+**Source:** Sa et al. (2026)
+
+Systematic review cites 29% alcohol reduction with dulaglutide and notes 'potential benefits in SUD' as an emerging therapeutic application. Review characterizes this as operating through reward pathway modulation consistent with mesolimbic dopamine mechanism.

inbox/archive/health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: medium
 tags: [glp-1, psychiatry, systematic-review, depression, anhedonia, suicidality, meta-analysis]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content